This page contains a Flash digital edition of a book.
Systems Pharmacology


Dr Dustin P. Martin is a research scientist at the Medical College of Wisconsin (Milwaukee, Wisconsin, USA). He has served as an Adjunct Professor of Biology at both St Mary’s University and Winona State University (both in Winona, Minnesota, USA). His current research interests include systems pharmacology predicated on pep- tide-based anti-inflammatory peptides in a number of neutrophil-mediated diseases such as stroke, traumatic brain injury, sickle cell disease and bron- chopulmonary dysplasia. In addition he has research and entrepreneurial interests in neurode- generative diseases such as prion-mediated diseases and Alzheimer’s Disease. He received his PhD in Neuroscience and Molecular, Cellular and Developmental Biology from Iowa State University.


Dr Stephen Naylor is a Co-Founder, CEO and Board Chairman of ReNeuroGen LLC, a virtual pharmaceutical company developing systems phar- macology therapies for the treatment of neurologi- cal diseases. He is also a Co-Founder, COO and Board Chairman of iMetabolic Biopharma Corporation. In addition he is the Founder, Chairman and CEO of MaiHealth Inc, a systems/network biology level diagnostics compa- ny in the health/wellness and precision medicine sector. He was also the Founder, CEO and Chairman of Predictive Physiology & Medicine (PPM) Inc, one of the world’s first personalised medicine companies. He serves also as an Advisory Board Member of CureHunter Inc, a computation- al biology drug discovery company, and as a busi- ness adviser to the not-for-profit Cures Within Reach. In the past he has held professorial chairs in Biochemistry & Molecular Biology; Pharmacol- ogy; Clinical Pharmacology and Biomedical Engineering, all at Mayo Clinic in Rochester, MN, USA. He holds a PhD from the University of Cambridge (UK), and undertook a NIH-funded fellowship at MIT located in the ‘other’ Cambridge, USA. Address correspondence to him at snaylor@rngen.com.


Continued from page 42


35 Ramsey, RR et al. A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases. Clin. Transl. Med. 7, (2018) doi: 10.1186/s40169-017-0181-2. 36 Thiel, C et al. Using Quantitative Systems Pharmacology to Evaluate the Drug Efficacy of COX-2 and 5- LOX Inhibitors in Therapeutic Situations. Using Quantitative Systems Pharmacology to Evaluate the Drug Efficacy of COX-2 and 5-LOX Inhibitors in Therapeutic Situations. Systems Biol. Appl. Article Number 28 (2018). doi.org/10.1038/s41540-018- 0062-3. 37 Lin, H-H, Zhang, L-L, Yan, R et al. Network Analysis of Drug–Target Interactions: A Study on FDA-Approved New Molecular Entities Between 2000 to 2015. Science Reports.7, Article Number 12230, (2017). doi: 10.1038/s41598-017-12061-8. 38 De Castro, S and Camarasa, M-J. Can a Drug with Simultaneous Action Against Two Relevant Targets be an Alternative to Combination Therapy? Eur. J. Med Chem. 150, 206-227 (2018).


Drug Discovery World Winter 2018/19


43


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68